LMWHn
LMWHn is a term used in some research contexts to denote nano-formulated low-molecular-weight heparin, a class of anticoagulant systems that combine low-molecular-weight heparin with nanotechnology-based carriers. The concept aims to modify pharmacokinetics and distribution of LMWH by attaching or encapsulating it within nanoscale delivery systems such as polymeric, lipid-based, or hybrid nanoparticles. In proposed designs, LMWH may be chemically conjugated to a carrier or loaded into a nanocarrier, allowing controlled release and, in some cases, site-specific or tissue-targeted delivery.
Mechanistically, LMWHn seeks to preserve the anticoagulant activity of LMWH, primarily through interaction with antithrombin III
Potential advantages discussed in early-stage work include more predictable pharmacokinetics, reduced dosing frequency, enhanced targeting to
Challenges and safety considerations are substantial. Manufacturing complexity, nanoparticle stability, potential immunogenicity, and nanoparticle-related toxicity are